Shawn D. Aaron; Katherine L. Vandemheen; Dean Fergusson; François Maltais; Jean Bourbeau; Roger Goldstein; Meyer Balter; Denis O'Donnell; Andrew McIvor; Sat Sharma; Graham Bishop; John Anthony; Robert Cowie; Stephen Field; Andrew Hirsch; Paul Hernandez; Robert Rivington; Jeremy Road; Victor Hoffstein; Richard Hodder; Darcy Marciniuk; David McCormack; George Fox; Gerard Cox; Henry B. Prins; Gordon Ford; Dominique Bleskie; Steve Doucette; Irvin Mayers; Kenneth Chapman; Noe Zamel; Mark FitzGerald;
Scant evidence supports prescribing combinations of inhaled corticosteroids and long-acting β-agonists and anticholinergic bronchodilators for chronic obstructive pulmonary disease (COPD). Investigators randomly assigned 449 adults with moderate or severe COPD to receive tiotropium with placebo, with salmeterol, or with fluticasone–salmeterol for 1 year. The exacerbation rates for the 3 groups were 63%, 65%, and 60%, respectively. Compared with tiotropium alone, 3-drug therapy but not 2-drug therapy had fewer exacerbations requiring hospitalization.
Ann Intern Med. 2007;146(8):545-555. doi:10.7326/0003-4819-146-8-200704170-00152
Dino Vaira; Angelo Zullo; Nimish Vakil; Luigi Gatta; Chiara Ricci; Federico Perna; Cesare Hassan; Veronica Bernabucci; Andrea Tampieri; Sergio Morini
Eradication rates of Helicobacter pylori infection are decreasing worldwide because of increasing resistance to antimicrobials. In this double-blind trial, 300 adults with dyspepsia or peptic ulcers were randomly assigned to a 10-day sequential regimen (pantoprazole, amoxicillin, and placebo taken for 5 days followed by pantoprazole, clarithromycin, and tinidazole taken for 5 days) or standard 10-day therapy (pantoprazole, clarithromycin, and amoxicillin). The eradication rate was higher with the sequential regimen than with standard therapy, especially in patients with clarithromycin-resistant strains. The incidence of side effects did not differ between groups.
Ann Intern Med. 2007;146(8):556-563. doi:10.7326/0003-4819-146-8-200704170-00006
Jean B. Nachega; Michael Hislop; David W. Dowdy; Richard E. Chaisson; Leon Regensberg; Gary Maartens
Protease-based HIV treatment regimens require 95% or higher adherence to achieve optimal viral load suppression. Nachega and colleagues asked whether regimens based on nonnucleoside reverse transcriptase inhibitors (NNRTIs) require the same high level of adherence. They reviewed pharmacy claim records and virologic responses in 2821 HIV-infected adults enrolled in an HIV/AIDS disease management program in South Africa. After a 2.2-year follow-up, 25% of patients who had 50% to 60% adherence achieved viral load suppression, a rate that increased linearly to 73% of those who had 90% to 100% adherence with NNRTI–based therapy. Better adherence increases the chance of success, but the requirement for adherence appears less stringent than that of regimens that do not contain NNRTIs.
Ann Intern Med. 2007;146(8):564-573. doi:10.7326/0003-4819-146-8-200704170-00007
Joan Gavaldà; Oscar Len; José M. Miró; Patricia Muñoz; Miguel Montejo; Aristides Alarcón; Julián de la Torre-Cisneros; Carmen Peña; Xavier Martínez-Lacasa; Cristina Sarria; Germán Bou; José M. Aguado; Enrique Navas; Joan Romeu; Francesc Marco; Carmen Torres; Pilar Tornos; Ana Planes; Vicenç Falcó; Benito Almirante; Albert Pahissa
A 4- to 6-week course of penicillin or ampicillin plus an aminoglycoside is currently recommended for treating enterococcal endocarditis. However, this regimen is ineffective against Enterococcus faecalis organisms with high-level aminoglycoside resistance (HLAR). Gavaldà and colleagues evaluated the efficacy and safety of ampicillin plus ceftriaxone for treating E. faecalis endocarditis in patients who could not tolerate aminoglycosides because of nephrotoxicity. Twenty- one patients had HLAR organisms and 22 patients did not. A 6-week course effectively treated both groups.
Ann Intern Med. 2007;146(8):574-579. doi:10.7326/0003-4819-146-8-200704170-00008
Stephan Reichenbach; Rebekka Sterchi; Martin Scherer; Sven Trelle; Elizabeth Bürgi; Ulrich Bürgi; Paul A. Dieppe; Peter Jüni
Many physicians use oral chondroitin, a highly hydrophilic, gel-forming polysaccharide macromolecule, to treat osteoarthritis. Meta-analyses of clinical trials have described moderate to large benefits of chondroitin, but recent large-scale trials did not find evidence of an effect. Reichenbach and colleagues performed a systematic review of randomized, controlled trials to determine the effect of chondroitin on pain and joint space width. They found little or no symptomatic benefit of chondroitin in the recent high-quality large-scale trials, and they discourage using chondroitin in routine clinical practice.
Ann Intern Med. 2007;146(8):580-590. doi:10.7326/0003-4819-146-8-200704170-00009
Myron S. Cohen; Cynthia Gay; Angela D.M. Kashuba; Sally Blower; Lynn Paxton
Antiretroviral therapy (ART) has prolonged and improved the lives of persons with HIV infection. Cohen and colleagues reviewed relevant publications on the use of ART to prevent the sexual transmission of HIV and discuss 3 ways that ART can prevent sexual transmission of HIV: 1) effective treatment of HIV-infected persons to reduce transmission to sexual partners, 2) nonoccupational postexposure prophylaxis, and 3) preexposure prophylaxis.
Ann Intern Med. 2007;146(8):591-601. doi:10.7326/0003-4819-146-8-200704170-00010
R. Scott Braithwaite; Allison B. Rosen
The rationale for cost sharing is often a moral hazard argument—that individuals may overuse care if they do not share its costs. In practice, people apply the concept of cost sharing without taking into account the clinical value of the service. Cost sharing could be harmful if it discouraged patients from using high-value services. The authors distinguish between appropriate (low ratio of benefits to costs) and inappropriate (high ratio of benefits to costs) settings for cost sharing and discuss how cost-effectiveness analysis can help policymakers to decide when cost-sharing policies are appropriate. Systematic efforts to discourage inappropriate cost sharing may improve public health.
Ann Intern Med. 2007;146(8):602-605. doi:10.7326/0003-4819-146-8-200704170-00011
Gerard J. Criner
In this issue, Aaron and colleagues performed a randomized trial in which all patients with moderate to severe COPD received tiotropium with random assignment to placebo, a long-acting inhaled bronchodilator (salmeterol), or a combination of inhaled corticosteroid (fluticasone) and salmeterol. The primary outcome, the total exacerbation rate, was the same in all 3 groups. Relative to tiotropium alone, tiotropium plus fluticasone–salmeterol benefited several secondary outcomes: severe exacerbations that required hospitalization, lung function, and quality of life. Studies such as this suggest that we may finally be on the threshold of therapies that decrease the morbidity and mortality of COPD.
Ann Intern Med. 2007;146(8):606-608. doi:10.7326/0003-4819-146-8-200704170-00012
Julio S.G. Montaner; Robert S. Hogg
Expansion of highly active antiretroviral therapy (HAART) programs in South Africa and other low- and medium-income nations should remain a top priority. In this issue, Nachega and colleagues used pharmacy refill or claim data to measure adherence to nonnucleoside reverse transcriptase inhibitor–based HAART in patients in a private-sector, publicly sponsored HIV/AIDS program in South Africa. Increasing adherence was associated with an increase in the probability of sustained virologic suppression at all levels of adherence beyond 50%. The authors' approach to measuring adherence could become an important tool to evaluate the effectiveness of public-sector programs in low- and medium-income nations.
Ann Intern Med. 2007;146(8):609-610. doi:10.7326/0003-4819-146-8-200704170-00013
David T. Felson
In this issue, Reichenbach and colleagues studied the 20 trials that have compared chondroitin with placebo or no treatment for pain in osteoarthritis of the hip or knee. The results varied widely. The best current evidence, from 3 large high-quality trials, states that chondroitin sulfate does not reduce joint pain in osteoarthritis. Nevertheless, some patients are convinced that it helps. Since frequent or severe adverse effects have not been reported, a trial of chondroitin sulfate may be worthwhile.
Ann Intern Med. 2007;146(8):611-612. doi:10.7326/0003-4819-146-8-200704170-00014
Ann Intern Med. 2007;146(8):613. doi:10.7326/0003-4819-146-8-200704170-00015
Ann Intern Med. 2007;146(8):613. doi:10.7326/0003-4819-146-8-200704170-00016
Ann Intern Med. 2007;146(8):613-614. doi:10.7326/0003-4819-146-8-200704170-00017
Ann Intern Med. 2007;146(8):614. doi:10.7326/0003-4819-146-8-200704170-00018
Ann Intern Med. 2007;146(8):614. doi:10.7326/0003-4819-146-8-200704170-00019
Ann Intern Med. 2007;146(8):614-615. doi:10.7326/0003-4819-146-8-200704170-00020
Ann Intern Med. 2007;146(8):615. doi:10.7326/0003-4819-146-8-200704170-00021
Ann Intern Med. 2007;146(8):615-616. doi:10.7326/0003-4819-146-8-200704170-00022
Ann Intern Med. 2007;146(8):616. doi:10.7326/0003-4819-146-8-200704170-00023
Ann Intern Med. 2007;146(8):616. doi:10.7326/0003-4819-146-8-200704170-00024
Jennifer Fisher Wilson
Ann Intern Med. 2007;146(8):617-620. doi:10.7326/0003-4819-146-8-200704170-00025
Ann Intern Med. 2007;146(8):I-20. doi:10.7326/0003-4819-146-8-200704170-00002
Ann Intern Med. 2007;146(8):I-28. doi:10.7326/0003-4819-146-8-200704170-00003
Ann Intern Med. 2007;146(8):I-56. doi:10.7326/0003-4819-146-8-200704170-00004
Ann Intern Med. 2007;146(8):I-12. doi:10.7326/0003-4819-146-8-200704170-00153
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use